FDx Advisors Inc. Has $2.29 Million Position in Bristol-Myers Squibb Co (BMY)

FDx Advisors Inc. increased its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 3.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 35,970 shares of the biopharmaceutical company’s stock after acquiring an additional 1,132 shares during the period. FDx Advisors Inc.’s holdings in Bristol-Myers Squibb were worth $2,293,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in Bristol-Myers Squibb by 0.3% in the 2nd quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock worth $6,611,829,000 after buying an additional 333,685 shares in the last quarter. BlackRock Inc. grew its stake in Bristol-Myers Squibb by 2.4% in the 2nd quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock worth $5,541,612,000 after buying an additional 2,367,864 shares in the last quarter. Dodge & Cox grew its stake in Bristol-Myers Squibb by 1.6% in the 2nd quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock worth $1,648,168,000 after buying an additional 459,271 shares in the last quarter. Jennison Associates LLC grew its stake in Bristol-Myers Squibb by 16.2% in the 3rd quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock worth $1,711,689,000 after buying an additional 3,735,453 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Bristol-Myers Squibb by 3.9% in the 2nd quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock worth $1,339,612,000 after buying an additional 910,496 shares in the last quarter. 69.67% of the stock is currently owned by institutional investors and hedge funds.

BMY has been the subject of a number of research reports. Citigroup set a $72.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Jefferies Group reissued a “buy” rating and issued a $72.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, September 27th. Vetr raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.50 price target for the company in a research note on Wednesday, September 27th. UBS Group reaffirmed a “buy” rating and issued a $72.00 price objective (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Finally, SunTrust Banks raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $65.05.

Shares of Bristol-Myers Squibb Co (NYSE BMY) opened at $62.01 on Thursday. Bristol-Myers Squibb Co has a 12 month low of $46.01 and a 12 month high of $66.10. The stock has a market cap of $101,490.00, a price-to-earnings ratio of 24.41, a PEG ratio of 2.22 and a beta of 1.18. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. During the same period last year, the company posted $0.77 EPS. Bristol-Myers Squibb’s revenue for the quarter was up 6.7% on a year-over-year basis. analysts forecast that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be given a dividend of $0.40 per share. The ex-dividend date is Thursday, January 4th. This represents a $1.60 annualized dividend and a yield of 2.58%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio is presently 62.99%.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Theodore R. Samuels II purchased 4,000 shares of the company’s stock in a transaction on Friday, December 15th. The shares were purchased at an average cost of $62.30 per share, with a total value of $249,200.00. Following the transaction, the director now directly owns 22,000 shares in the company, valued at $1,370,600. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.

WARNING: “FDx Advisors Inc. Has $2.29 Million Position in Bristol-Myers Squibb Co (BMY)” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.com-unik.info/2018/01/11/fdx-advisors-inc-has-2-29-million-position-in-bristol-myers-squibb-co-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

What are top analysts saying about Bristol-Myers Squibb? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bristol-Myers Squibb and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit